PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-29.38%
Cash & equivalents declining -29.38% while CRVO's grows 225.19%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-29.38%
Below half of CRVO's 225.19%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Current Assets Growth compared to CRVO's zero value, indicating worse performance.
-29.50%
Below half of CRVO's 1839.11%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-29.38%
Below half of CRVO's 1537.87%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-13.35%
Less than half of CRVO's 13.72%. David Dodd sees a more disciplined AP approach or lower volume.
-100.00%
Less than half of CRVO's 24.10%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both CRVO and the company show zero Deferred Revenue (Current) Growth.
-6.76%
Less than half of CRVO's 1.11%. David Dodd sees fewer expansions in other current obligations.
-9.79%
Less than half of CRVO's 9.17%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.79%
Less than half of CRVO's 9.17%. David Dodd sees far fewer liability expansions relative to competitor.
0.31%
Less than half of CRVO's 5.18%. David Dodd sees fewer share issuances vs. competitor.
-2.40%
Below half CRVO's -6.25%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-68.44%
Below half CRVO's 26.38%. Michael Burry sees potential underperformance in building shareholder capital.
-29.38%
Below half CRVO's 1537.87%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Less than half of CRVO's 24.10%. David Dodd sees less overall debt expansion vs. competitor.
28.92%
Above 1.5x CRVO's 16.18%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.